Breaking News

Successful Sterile Inspection for Scottish CMO

Symbiosis has been re-inspected and approved for the ongoing production of IMPs for clinical trials

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Injectable manufacturing specialist Symbiosis Pharmaceutical Services has successfully completed a scheduled inspection from the UK Government Regulator, the Medicines and Healthcare products Regulatory Agency (MHRA).

The contract manufacturing organization (CMO) received no critical or major observations.

Symbiosis has been re-inspected and approved for the ongoing production of investigational medicinal products (IMPs) for clinical trials. In a further boost to support the growth and strategic development of the company, it received confirmation of continued authorization for the GMP-manufacture of aseptically filled licensed commercial products following initial approval of the commercial manufacturer/importer (MIA) license last year.

The regulatory inspection and approval of Symbiosis’ Scotland-based facility comes in the wake of several high profile pull outs and inspection failures at sterile pharmaceutical manufacturing facilities globally.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters